Martelli et al., 2009 - Google Patents

N, N-bis (cyclohexanol) amine aryl esters: a new class of highly potent transporter-dependent multidrug resistance inhibitors

Martelli et al., 2009

View PDF
Document ID
539272218339455851
Author
Martelli C
Alderighi D
Coronnello M
Dei S
Frosini M
Le Bozec B
Manetti D
Neri A
Romanelli M
Salerno M
Scapecchi S
Mini E
Sgaragli G
Teodori E
Publication year
Publication venue
Journal of medicinal chemistry

External Links

Snippet

A new series of Pgp-dependent MDR inhibitors having a N, N-bis (cyclohexanol) amine scaffold was designed on the basis of the frozen analogue approach. The scaffold chosen gives origin to different geometrical isomers. The new compounds showed a wide range of …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (-N=N-), diazo (=N2), azoxy (>N-O-N< or N(=O)-N<), azido (-N3) or diazoamino (-N=N-N<) compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom

Similar Documents

Publication Publication Date Title
Chen et al. Discovery of O-alkylamino-tethered niclosamide derivatives as potent and orally bioavailable anticancer agents
Yang et al. Design and synthesis of janus kinase 2 (JAK2) and histone deacetlyase (HDAC) bispecific inhibitors based on pacritinib and evidence of dual pathway inhibition in hematological cell lines
Tang et al. Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors
Das et al. Structure–Activity Relationship and Molecular Mechanisms of Ethyl 2-Amino-6-(3, 5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4 H-chromene-3-carboxylate (CXL017) and Its Analogues
Teodori et al. Design, synthesis, and in vitro activity of catamphiphilic reverters of multidrug resistance: discovery of a selective, highly efficacious chemosensitizer with potency in the nanomolar range
Cong et al. An indole–chalcone inhibits multidrug-resistant cancer cell growth by targeting microtubules
Binaschi et al. Antiproliferative and differentiating activities of a novel series of histone deacetylase inhibitors
Qiu et al. Design, Synthesis, and Pharmacological Characterization of N-(4-(2 (6, 7-Dimethoxy-3, 4-dihydroisoquinolin-2 (1 H) yl) ethyl) phenyl) quinazolin-4-amine Derivatives: Novel Inhibitors Reversing P-Glycoprotein-Mediated Multidrug Resistance
Ko et al. Development of a chimeric c-Src kinase and HDAC inhibitor
Baruchello et al. Novel 3, 4-isoxazolediamides as potent inhibitors of chaperone heat shock protein 90
Fruttero et al. Phenylsulfonylfuroxans as modulators of multidrug-resistance-associated protein-1 and P-glycoprotein
Qiu et al. Exploration of 2-((pyridin-4-ylmethyl) amino) nicotinamide derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance
JP5363983B2 (en) Tetrasubstituted NDGA derivatives via ether and carbamate bonds and their synthesis and pharmaceutical use
Dei et al. Modulation of the spacer in N, N-bis (alkanol) amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators
Li et al. Discovery of the polyamine conjugate with benzo [cd] indol-2 (1 H)-one as a lysosome-targeted antimetastatic agent
Martelli et al. N, N-bis (cyclohexanol) amine aryl esters: a new class of highly potent transporter-dependent multidrug resistance inhibitors
Ai et al. 5-((3-Amidobenzyl) oxy) nicotinamides as Sirtuin 2 Inhibitors
Wang et al. Discovery of the triazolo [1, 5-a] pyrimidine-based derivative WS-898 as a highly efficacious and orally bioavailable ABCB1 inhibitor capable of overcoming multidrug resistance
Odell et al. Pyrimidine-based inhibitors of dynamin I GTPase activity: competitive inhibition at the Pleckstrin homology domain
Guglielmo et al. Structure–Activity Relationship Studies on Tetrahydroisoquinoline Derivatives:[4′-(6, 7-Dimethoxy-3, 4-dihydro-1 H-isoquinolin-2-ylmethyl) biphenyl-4-ol](MC70) Conjugated through Flexible Alkyl Chains with Furazan Moieties Gives Rise to Potent and Selective Ligands of P-glycoprotein
Brennecke et al. Cannabinoid receptor type 2 ligands: an analysis of granted patents since 2010
Dei et al. Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N, N-bis (alkanol) amine aryl esters
Qiu et al. Exploration of Janus kinase (JAK) and histone deacetylase (HDAC) bispecific inhibitors based on the moiety of fedratinib for treatment of both hematologic malignancies and solid cancers
Peng et al. Discovery of novel acridane-based tubulin polymerization inhibitors with anticancer and potential immunomodulatory effects
Zhao et al. Synthesis and evaluation of noviose replacements on novobiocin that manifest antiproliferative activity